Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

References

• Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018;27(12):1984–2009. doi:10.1002/pro.351930267440
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161–170. doi:10.1056/NEJMra120211723301733
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127–140. doi:10.1038/nrd326421283107
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kantarjian HM, Kiladjian JJ, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized Phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139–1145. doi:10.3324/haematol.2014.11954526069290
   PubMed Web of Science ®Google Scholar
• Mesa RA, Kiladjian JJ, Verstovsek S, et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the Phase 3 COMFORT studies. Haematologica. 2014;99(2):292–298. doi:10.3324/haematol.2013.08765023911705
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435. doi:10.1056/NEJMoa140900225629741
   PubMed Web of Science ®Google Scholar
• Anand K, Burns EA, Ensor J, Rice L, Pingali SR. Mycobacterial infections with ruxolitinib: a retrospective pharmacovigilance review. Clin Lymphoma Myeloma Leuk. 2020;20(1):18–23. doi:10.1016/j.clml.2019.08.00831699655
   PubMed Web of Science ®Google Scholar
• Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339–347. doi:10.1002/ajh.2497629150886
   PubMed Web of Science ®Google Scholar
• Branco B, Metsu D, Dutertre M, et al. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol. 2016;95(7):1207–1209. doi:10.1007/s00277-016-2684-027113251
   PubMed Web of Science ®Google Scholar
• Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma. 2015;56(5):1528–1529. doi:10.3109/10428194.2014.96308225213182
   PubMed Web of Science ®Google Scholar
• Shamil E, Cunningham D, Wong BL, Jani P. Ruxolitinib associated tuberculosis presenting as a neck lump. Case Rep Infect Dis. 2015;2015:284168.26788384
   PubMedGoogle Scholar
• Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. 2012;5(1):552. doi:10.1186/1756-0500-5-55223039051
   PubMedGoogle Scholar
• Palandri F, Polverelli N, Catani L, Vianelli N. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol. 2015;94(3):519–520. doi:10.1007/s00277-014-2183-025172457
   PubMed Web of Science ®Google Scholar
• Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia. 2014;28(8):1750–1751. doi:10.1038/leu.2014.10424625550
   PubMed Web of Science ®Google Scholar
• Abidi MZ, Haque J, Varma P, et al. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol. 2016;2016:2389038.27843657
   PubMedGoogle Scholar
• Tsukamoto Y, Kiyasu J, Tsuda M, et al. Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis: a case report and review of the literature. Intern Med. 2018;57(9):1297–1300. doi:10.2169/internalmedicine.9165-1729279479
   PubMed Web of Science ®Google Scholar
• Lescuyer S, Ledoux MP, Gravier S, et al. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. Int J Infect Dis. 2019;80:134–136. doi:10.1016/j.ijid.2019.01.00230639623
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-64354427069254
   PubMed Web of Science ®Google Scholar
• Schönberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75(11):2187–2199. doi:10.1158/0008-5472.CAN-14-319825832652
   PubMed Web of Science ®Google Scholar
• Heine A, Held SA, Daecke SN, et al. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013;122(7):1192–1202. doi:10.1182/blood-2013-03-48464223770777
   PubMed Web of Science ®Google Scholar
• Elli EM, Baratè C, Mendicino F, Palandri F, Palumbo GA. Mechanisms underlying the anti-inflammatory and Immunosuppressive activity of ruxolitinib. Front Oncol. 2019;9:1186. doi:10.3389/fonc.2019.0118631788449
   PubMed Web of Science ®Google Scholar
• Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy. BMJ Case Rep. 2014;2014(jun02 1):bcr2014204950. doi:10.1136/bcr-2014-204950
   Google Scholar
• Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated with ruxolitinib. N Engl J Med. 2013;369(7):681–683. doi:10.1056/NEJMc130289523944322
   PubMed Web of Science ®Google Scholar
• Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143(5):1478–1479. doi:10.1378/chest.12-160423648912
   PubMed Web of Science ®Google Scholar
• Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy associated with ruxolitinib. N Engl J Med. 2013;369(2):197–198. doi:10.1056/NEJMc1302135
   PubMed Web of Science ®Google Scholar
• Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28(1):225–227. doi:10.1038/leu.2013.23523929216
   PubMed Web of Science ®Google Scholar
• Abedin S, McKenna E, Chhabra S, et al. Efficacy, Toxicity, and infectious complications in ruxolitinib-treated patients with corticosteroid-refractory graft-versus-host disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(8):1689–1694. doi:10.1016/j.bbmt.2019.04.00330965140
   PubMed Web of Science ®Google Scholar
• Maschmeyer G, De Greef J, Mellinghoff SC, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33(4):844–862. doi:10.1038/s41375-019-0388-x30700842
   PubMed Web of Science ®Google Scholar
• Sanai FM, Bzeizi KI. Systematic review: tuberculous peritonitis–presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther. 2005;22(8):685–700. doi:10.1111/j.1365-2036.2005.02645.x16197489
   PubMed Web of Science ®Google Scholar
• Wu DC, Averbukh LD, Wu GY. Diagnostic and therapeutic strategies for peritoneal tuberculosis: a review. J Clin Transl Hepatol. 2019;7(2):140–148. doi:10.14218/JCTH.2018.0006231293914
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Kapur S, Kinkhabwala M, Cello JP. The laparoscopic evaluation of ascites. Gastrointest Endosc Clin N Am. 2001;11(1):79–91. doi:10.1016/S1052-5157(18)30088-611175976
   PubMedGoogle Scholar
• Bhargava DK, Gupta M, Nijhawan S, Dasarathy S, Kushwaha AK. Adenosine deaminase (ADA) in peritoneal tuberculosis: diagnostic value in ascitic fluid and serum. Tubercle. 1990;71(2):121–126. doi:10.1016/0041-3879(90)90007-U2219461
   PubMedGoogle Scholar
• Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis. J Clin Gastroenterol. 2006;40(8):705–710. doi:10.1097/00004836-200609000-0000916940883
   PubMed Web of Science ®Google Scholar
• Lee YM, Park KH, Kim SM, et al. Risk factors for false-negative results of T-SPOT.TB and tuberculin skin test in extrapulmonary tuberculosis. Infection. 2013;41(6):1089–1095. doi:10.1007/s15010-013-0478-z23943073
   PubMed Web of Science ®Google Scholar